---
figid: PMC4090290__nihms553100f1
figtitle: Epidermal growth factor receptor (EGFR) pathway activation during HNSCC
  carcinogenic process
organisms:
- Mus musculus
- Cricetus cricetus
- Homo sapiens
- Nicotiana tabacum
pmcid: PMC4090290
filename: nihms553100f1.jpg
figlink: /pmc/articles/PMC4090290/figure/F1/
number: F1
caption: Epidermal growth factor receptor (EGFR) pathway activation during HNSCC carcinogenic
  process. Loss of heterozigosity (LOH), EGFR overexpression/amplification and cyclooxygenase-2
  (COX2) dysregulation in pre-malignant lesions have been associated with invasive
  cancer risk. EGFR activation contributes to acquisition of cancer hallmarks represented
  in the figure. EGFR can be inhibited by the use of monoclonal antibodies (cetuximab,
  panitumumab, zalatumumab) and tyrosine kinase inhibitors (erlotinib, gefitinib,
  vandetanib and afatinib). Vandetanib and afatinib exhibit multikinase activity against
  other targets such as the vascular endothelial growth factor (VEGF) receptor (vandetanib)
  and HER-2 (afatinib).
papertitle: Targeting the Epidermal Growth Factor Receptor for Head and Neck Cancer
  Chemoprevention.
reftext: Milena P. Mak, et al. Oral Oncol. ;50(10):918-923.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.96117
figid_alias: PMC4090290__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC4090290__F1
ndex: 2f397f1c-dedc-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4090290__nihms553100f1.html
  '@type': Dataset
  description: Epidermal growth factor receptor (EGFR) pathway activation during HNSCC
    carcinogenic process. Loss of heterozigosity (LOH), EGFR overexpression/amplification
    and cyclooxygenase-2 (COX2) dysregulation in pre-malignant lesions have been associated
    with invasive cancer risk. EGFR activation contributes to acquisition of cancer
    hallmarks represented in the figure. EGFR can be inhibited by the use of monoclonal
    antibodies (cetuximab, panitumumab, zalatumumab) and tyrosine kinase inhibitors
    (erlotinib, gefitinib, vandetanib and afatinib). Vandetanib and afatinib exhibit
    multikinase activity against other targets such as the vascular endothelial growth
    factor (VEGF) receptor (vandetanib) and HER-2 (afatinib).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - COX2
  - Ptgs2
  - Egfr
  - Tgfa
  - Egf
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Zhx2
  - Jak2
  - Akt1
  - Stat3
  - Mtor
  - Vegfa
  - PTGS2
  - MTCO2P12
  - EGFR
  - TGFA
  - EGF
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - JAK2
  - AKT1
  - AKT2
  - AKT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - STAT3
  - MTOR
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - Vandetanib
  - Cancer
  - Lung cancer
---
